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however, cerebral ischaemia leads to a rapid accumulation of free arachidonic acid, 41 prostanoids 1, 2 -5 -" and lipid peroxides 41 in ischaemic regions. Products of arachidonic acid cyclooxygenation (prostaglandins and thromboxane A 2 ) and lipoxydation (lipid peroxides and leukotriens) are believed to play a major role in cerebral vasoconstriction, 15 ' 2737 ' 39 oedema 5 and neurotoxic phenomena 4 ' 41 which are characteristic of the postischaemic reperfusion period.
Among dienoic prostanoids prostacyclin (PGI 2 ) is the only one that relaxes cerebral arteries of humans, 8 ,27 baboons 8 and dogs 11, 28 whereas prostaglandins A 2 , B 2 , D 2 , E 2 , F 2Q and thromboxane A 2 (TXA 2 ) contract cerebral arteries 3 ' 8 - 14, 15, 37 or have little effect on their tone. 27 The physiological role of prostanoids in the regulation of cerebral blood flow (CBF) is debatable. 6,9 ' 28,32 However in ischaemic canine brain 16, 21, 22, 38, 39 and in infarcted rat brain 7, 10 prostanoids are released and are responsible for cerebral vasoconstriction, brain oedema and neuronal hypermetabolism. Those phenomena are abolished by the treatment of cerebral ischaemia with PGI 2 , 7,21 " 23,39 with cyclooxygenase inhibitors [21] [22] [23] 39 or with thromboxane synthetase inhibitors. 39 In summary, cerebral ischaemia is associated with a local release of free arachidonic acid and its lipoxydation products. 41 Lipid peroxides cause a further damage to cell membranes and inhibit PGI 2 synthetase. 18 Thereby a subsequent cyclooxygenation of arachidonic acid yields only vasoconstrictor prostanoids which contribute to postischaemic hypoperfusion, 22, 39 brain oedema 5 and neuronal hypermetabolism. 23 Prostacyclin deficiency also promotes formation of platelet microthrombi in the cerebral circulation and it facilitates the release of vasoconstrictory TXA 2 , PGF 2a and 5-HT from aggregating platelets. Here, we report on the administration of prostacyclin therapy to ten patients with ischaemic stroke.
Patients and Methods
Ten patients with ischaemic stroke (tables 1 and 2) were treated with prostacyclin (PGI 2 ) not earlier than 1 day and not later than 5 days after hospital admission. Consent for this clinical trial was signed by the closest family member or by the patients themselves when this was possible. Patients with transient ischaemic attacks (TIA), cerebral or subarachnoid haemorrhages were excluded by neurological examination, by cerebrospinal fluid (CSF) analysis and by angiography.
Unilateral cerebral angiography, by direct carotid artery puncture was performed on all patients, of whom eight had partial or complete occlusion of the internal carotid artery or of a major cerebral artery and two patients showed diffuse atherosclerosis of the internal carotid and intracranial arteries (table 2) . In all patients, diffuse or focal pathological discharges from the affected hemisphere were recorded by EEG examination (table 3). In one patient (#4) focal temporal and parietal discharges were associated with unilateral epileptic-like twitches. Five of the patients had hemiplegia and five had hemiparesis. Three patients had motor-sensory aphasia and all patients showed signs of disturbed function of some of the cranial nerves. Two patients were in a semicomatose state (table 1) . In all but two patients (#4 and #5) atherosclerotic or hypertensive changes in retinal blood vessels were observed. Pathological plantar (Babinski) responses were found in all patients, hemiparesthesia in four patients (#1, #2, #3 and #4) and sphincter disorders in four patients (#3, #4, #6 and #9).
None of the patients had a prior history of T.A. or ischaemic stroke; two had a history of arteriosclerosis obliterans in lower extremities and one of these (#9) suffered from a previous myocardial infarction. Two women (#7 and #8) were treated pharmacologically for arterial hypertension during last 5 years. All the men were heavy smokers and two of them (#2 and #6) chronic alcoholics. The commencement of the illness was not associated with acute trauma or infection in any of the patients. Some of the patients were given initial treatment with nicotinamide, tiamine pyrophosphate, procaine penicillin and, at a later stage, infusion of 5% glucose or an electrolyte solution, when necessary. No other drugs were employed.
Prostacyclin Neurological examination was performed immediately before the administration of PGI 2 , at the 1st, 3rd and 5th hours of the first course of the infusion of PGI 2 , at the end of each subsequent course and every day after the treatment had been stopped. In some patients fibrin(ogen) degradation products (FDP) in plasma (ADP) in platelet rich plasma (PRP) 20 -35 ' 36 were assessed at various periods of the infusion of PGI 2 ( fig. 1  and fig. 2 ). Two weeks after the termination of the therapy ipsilateral angiography was performed on two patients (#7 and #2). Bilateral angiography was performed on one patient (#J?) because of clinical symptoms suggestive of occlusion of the contralateral carotid artery. EEG was registered at various time intervals after termination of the treatment.
Results
The patients were observed for 7-11 weeks after the administration of PGI 2 . Rapid clinical improvement occurred in all the patients within 3-5 hours of the first course of the infusion of PGI 2 (table 4). Progressive improvement permitted six patients to leave the hospital within 4-8 weeks after PGI 2 therapy with full recovery of motor-sensory and speech function. Abnormal plantar responses were the only remaining neurological abnormalities. In three patients (#5, #9 and #8) after 7-8 weeks of observation a residual motor deficiency in upper extremities was still detectable whereas aphasia (#5), cortico-bulbar signs (#5, #9 and #8) and paresis of lower extremities completely disappeared, however, asymmetry in (tendon) reflexes persisted. In one patient (#3) the improvement was interrupted on the 14th day after the administration of PGI 2 ; contralateral involvement of the internal carotid artery was suggeested by the clinical symptoms; angiography confirmed internal carotid occlusion intracranially. This second event led to coma and death on the 9th day after the second episode.
In the first hours of administration of PGI 2 regression of hemiplegia and hemiparesis were the first to be observed. Active movements of lower and upper extremities were performed on the request. In parallel to that the first verbal contact with semi-comatose patients and patients with motor-sensory aphasia was reestablished. Next hours and days signs of injury to cranial nerves and hemiparesthesis disappeared. Disorders of sphincters and pathological reflexes persisted for a longer time.
After five days of PGI 2 administration we observed a disappearance of the slowing of the basic EEG rhythm as well as theta and delta waves when compared to the initial pattern of hemispheric asymmetry. EEG records in two patients became normal, in five patients close to normal, and in three patients a substantial remission of pathological discharges were observed (table 3) . Two weeks after the termination of the infusion of PGI 2 no pathological changes were detectable in the EEG of nine patients.
We had an opportunity to compare the unilateral cerebral angiography of two patients (#7 and #2) before and two weeks after the administration of PGI 2 . In contrast to the excellent clinical improvement in both patients (table 1) the local angiographic changes in the internal carotid artery did not improve. In the patient #7, the occlusion in the internal carotid artery extended by 3 cm down to the bifurcation.
Aggregation thresholds to ADP in PRP rose during the course of PGI 2 infusion and fell during the break periods. It seems that after the first two infusions of PGI 2 , platelets were sensitized to the antiaggregatory action of the subsequent PGI 2 infusions. Exhaustion of platelet responsiveness to the antiaggregatory action of PGI 2 was usually observed after the sixth course of the infusion of PGI 2 ( fig. 1) . A steady rise was observed in the FDP level up to the fourth course of PGI 2 treatment. During the later courses the FDP level had a tendency to come back to the initial level ( fig. 2 ). Side effects that were observed during infusions of PGI 2 are listed in table 4. None of them presented a serious clinical problem. Interestingly, a drop in arterial pressure was seen in only one patient whereas a moderate rise in systolic blood pressure (by 10-25 mm Hg) was observed in 7 patients. Paresthesia, melalgia, extrapyramidal movements similar to hemiballic or athetotic movements on the side of the paresis preceded the recovery of voluntary movements in the affected extremities. This period was frequently accompanied by a psychosomatic agitation.
Discussion
As early as a few hours after prostacyclin infusion, regression of hemiplegia or hemiparesis, disappearance of aphasia, and clearing of consciousness were observed. There was subsidence in one patient (#4) of focal epileptic-like attacks. In the next 4-8 weeks this improvement continued and allowed six patients to be discharged without significant residuam. Three other patients showed only a minor motor deficiency in the upper limb on the side of a previous hemiplegia. One patient died nine days following a sudden occlusion of the contralateral internal carotid artery which occurred two weeks after the termination of the infusion of PGI 2 . In all the patients the disappearance of the neurological manifestation of cerebral ischaemia was parallelled by disappearance of the electroencephalographic hemispheric asymmetry. Follow-up angiography indicated no evidence of change. We have no evidence of a disaggregatory 19 23 or a thromboxane inhibitor, 39 or a lipoxydase inhibitor. 4, 30 Most of the side effects which occurred during the intravenous administration of PGI 2 in the group of patients with stroke were similar to those reported previously in volunteers and patients 20 ' 29,35> 36 (table 4) . Additionally observed extrapyramidal involuntary movements, paresthesia and melalgia in paretic limbs were observed during the recovery period. Psychomotor agitation was seen in all the patients in conjunction with the first signs of subsidence of hemiplegia or hemiparesis.
The most striking side effect in the patients with stroke was a rise of systolic blood pressure by 10-25 mm Hg in 7 out of 10 patients who had received PGI 2 (table 4). In humans PGI 2 usually produces a fall in blood pressure and a modest tachycardia 29 although rise in blood pressure was reported in 3 out of 110 patients with peripheral vascular disease who had been treated with PGI 2 . 34 We have no explanation for the mechanism of hypertensive action of PGI 2 in patients with stroke. Suggestive evidence exists that increasing the arterial blood pressure by catecholamines, though hazardous, might be beneficial in stroke. 31 So far as the mechanism of the therapeutic effect of PGI 2 in stroke is concerned, we believe that PGI 2 selectively dilates the microvasculature, collateral arteries and major arteries in the ischaemic hemisphere. The reason for this selectivity is that vasoconstrictor prostanoids are generated by ischaemic cerebral tissue 1 ' 21617 ' 21 or alternatively are carried with arterial blood from the site of carotid stenosis. 39 Cerebral vessels that are contracted by PGF 2a or by 5-HT are easily relaxed by PGL,.
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' 27 This may account for the apparent therapeutic benefit observed in this series of ten patients.
Final conclusions will await further studies; the dramatic response in ten patients encourages further observations. Some of the subsequent studies must be conducted with appropriate regard for the need to include acceptable controls to validate observations about an exciting new potential for victims of ischaemic stroke.
